EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients

Fan Yang iD, Min Tang, Liang Cui, Jing Bai, Jiangyong Yu, Jiayi Gao, Xin Nie iD, Xu Li, Xuefeng Xia, Xin Yi, Ping Zhang, Lin Li iD

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Fan Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The biomarkers of immune checkpoint inhibitors in the treatment of non‐small cell lung cancer (NSCLC) patients have limited predictive performance. In this study we aimed to investigate the feasibility of molecular tumor burden index (mTBI) in circulating tumor DNA (ctDNA) as a predictor for immunotherapy in patients with NSCLC.

Methods

From February 2017 to November 2020, pretreatment and on‐treatment (3~6 weeks after first cycle of immunotherapy) dynamic plasma ctDNA samples from NSCLC patients receiving immune monotherapy or combination therapy were analyzed by targeted capture sequencing of 1021 genes. PyClone was used to infer the mTBI. The impact of pretreatment mTBI on survival outcomes was verified in the POPLAR/OAK trials.

Results

We found that patients without detectable baseline ctDNA had better survival outcomes (median overall survival [OS]: not reached vs. 12.8 months; hazard ratio [HR], 0.15; p = 0.035]). RB1 and SMARCA4 mutations were remarkably associated with worse survival outcomes. Furthermore, lower pretreatment mTBI was associated with superior OS (median: not reached vs. 8.1 months; HR, 0.22; p = 0.024) and PFS (median: 32.9 vs. 5.4 months; HR, 0.35; p = 0.045), but not objective response, which was validated in the POPLAR/OAK cohort, suggesting that baseline mTBI was a prognostic factor for NSCLC immunotherapy. Early dynamic changes of mTBI (ΔmTBI) significantly distinguished responsive patients, and patients with mTBI decrease to more than 68% at the final tumor evaluation had longer OS (median: 38.2 vs. 4.0 months; HR, 0.18; p = 0.017) and PFS (median: not reached vs. 2.3 months; HR, 0.24; p = 0.030).

Conclusion

ΔmTBI had a good sensitivity to identify potential beneficial patients based on the best effect CT scans, demonstrating that mTBI dynamics were predictive of benefit from immune checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPrognosisTumor BurdenBiomarkers, TumorDNA HelicasesNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

circulating tumor DNAimmunotherapymolecular tumor burden indexnon-small cell lung cancerprognostic

Substanzen

Biomarkers, TumorSMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
  • Geneplus-Beijing Institute, Beijing, People's Republic of China.

ORCID-Profile: Fan Yang, Xin Nie, Lin Li

Zitieren

APA

Yang, F., Tang, M., Cui, L., Bai, J., Yu, J., Gao, J., Nie, X., Li, X., Xia, X., Yi, X., Zhang, P., & Li, L. (2023). Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15098

Vancouver

Yang F, Tang M, Cui L, Bai J, Yu J, Gao J, et al. Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15098

BibTeX
@article{Yang2023,
  author = {Yang, Fan and Tang, Min and Cui, Liang and Bai, Jing and Yu, Jiangyong and Gao, Jiayi and Nie, Xin and Li, Xu and Xia, Xuefeng and Yi, Xin and Zhang, Ping and Li, Lin},
  title = {Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15098}
}
Kostenlos starten →